Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  News  >  Economy & Forex  >  All News

News : Economy & Forex

Latest NewsCompaniesMarketsEconomy & ForexCommoditiesInterest RatesBusiness LeadersFinance ProfessionalsCalendarSectors 
All NewsEconomyCurrencies / ForexCryptocurrenciesEconomic EventsPress releases

Pfizer separates consumer health unit in business rejig

share with twitter share with LinkedIn share with facebook
share via e-mail
0
07/11/2018 | 11:07pm CEST
The Pfizer logo is seen at their world headquarters in Manhattan, New York, U.S.

(Reuters) - Pfizer Inc announced plans on Wednesday to reorganize into three units, separating its consumer healthcare business that the U.S. drugmaker has been trying to sell since last year.

The company said it is still looking for options for the lower-margin, non-core consumer healthcare business that makes products ranging from painkiller Advil to lip balms and is worth about $15 billion.

"Given the lack of urgency, management is being rational about its divestiture," BMO Capital Markets analyst Alex Arfaei said, adding the new structure will help Pfizer maintain its options for the business.

The news comes a day after Pfizer deferred drug price increases for no more than six months, following criticism from U.S. President Donald Trump.

Starting 2019, Pfizer's new units would be Innovative Medicines, Established Medicines and Consumer Healthcare.

The company is currently split into two units - Innovative Medicines, which includes the consumer business, and Essential Health which houses legacy drugs such as Viagra.

"This design gives us a sharper focus on diverse patients in diverse markets," Albert Bourla, chief operating officer, said.

The innovative medicines business will include biosimilars and a new hospital business unit, and together with the consumer healthcare business, will account for about three-quarters of the company's revenue. Pfizer's 2017 annual revenue was $52.55 billion.

The established medicines unit would now include a majority of the company's brands such as soon-to-be off-patent neurological disease treatment Lyrica as well as some generic drugs.

The restructuring will allow the company to evaluate its businesses better and could result in selling or spinning off its off-patent drugs, Wall Street analysts said.

While the company expects the business to generate sustainable moderate revenue growth after Lyrica goes generic, Credit Suisse analyst Vamil Divan said the reorganization would allow the established medicines unit to have more autonomy.

"We believe the potential for Pfizer to ultimately sell or spin the business likely remains on the table over time," Divan said.

Pfizer shares were trading marginally down at $37.27 in early trading.

(Reporting by Manas Mishra in Bengaluru; Editing by Sweta Singh and Arun Koyyur)

By Manas Mishra

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news "Economy & Forex"
12:22aECOSOC UNITED NATIONS ECONOMIC AND SOCIAL COUNCI : Development More than Simple Conflict-Prevention Tool In Today’s Globalized World, Secretary-General Tells High-Level Political Forum
PU
12:02aTESTER : Farmers and Ranchers Are Being Used as Pawns in Trade War
PU
07/19Recovery Blogger Kelly Fitzgerald Junco Sells Memoir About Her Adventures as The ‘Sober Senorita’
SE
07/18ZIONS BANCORPORATION : U.S. regulatory panel gives Zions Bancorp green light to shed Fed oversight
RE
07/18IRFA TO EPA : Stop Going Rogue on RFS Read More...
PU
07/18MORGAN GRIFFITH : House Passes Loudermilk-Griffith Amendment to Stop Regulatory Overreach
PU
07/18Kinder Morgan Canada profit drops on lower crude shipments
RE
07/18PEW CHARITABLE TRUSTS : Colorado Governor Orders 'Orphan' Oil and Gas Wells Reduction
PU
07/18CITGO says CEO's U.S. visa has been revoked
RE
07/18NEWS HIGHLIGHTS : Top Global Markets News of the Day
DJ
Latest news "Economy & Forex"
Advertisement